Timolol treatment after myocardial infarction in diabetic patients

Diabetes Care
|May 1, 1983
PubMed

Insights

Long-term timolol treatment significantly reduced mortality and reinfarction in diabetic patients post-myocardial infarction. Diabetic patients responded similarly to non-diabetic patients, though slight carbohydrate intolerance was noted.

Area of Science:

  • Cardiology
  • Diabetology
  • Pharmacology

Background:

  • Diabetic patients face increased risks following myocardial infarction.
  • Beta-blocker therapy is standard post-myocardial infarction, but data in diabetics is limited.

Purpose of the Study:

  • To evaluate the efficacy of long-term timolol treatment in diabetic patients after myocardial infarction.
  • To compare outcomes between diabetic patients receiving timolol and placebo.

Main Methods:

  • Retrospective analysis of 99 diabetic patients from the Norwegian timolol multicenter study.
  • Timolol dosage: 10 mg twice daily; follow-up: 12-33 months (mean 17 months).

Main Results:

  • Timolol reduced overall mortality by 62.8% (P<0.05) and nonfatal reinfarction by 82.7% (P<0.05) compared to placebo.
  • Diabetic patients showed similar responses in side effects and withdrawals as non-diabetic patients.
  • A potential for slight carbohydrate intolerance with long-term timolol use was observed.

Conclusions:

  • Long-term timolol treatment is associated with significant reductions in mortality and reinfarction in diabetic patients post-myocardial infarction.
  • Diabetic patients tolerated timolol similarly to non-diabetic patients.
  • Prospective studies are needed to confirm these findings and monitor for carbohydrate intolerance.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...